NATIONAL INSTITUTES OF HEALTH
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Subsidiary, Private
- Established
- 1948-01-01
- Employees
- 1K
- Market Cap
- -
- Website
- http://www.nidcr.nih.gov
Testing the Safety of the Anti-cancer Drug, Sn-117m-DTPA, for Advanced Cancers That Have Spread to Bones
Phase 1
Not yet recruiting
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaMetastatic Lung Non-Small Cell CarcinomaMetastatic Malignant Neoplasm in the BoneMetastatic Prostate AdenocarcinomaStage IV Lung Cancer AJCC v8Stage IVB Prostate Cancer AJCC v8
- First Posted Date
- 2025-05-21
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 24
- Registration Number
- NCT06982222
Testing Whether Cemiplimab (REGN2810) Plus CDX-1140 Given Prior to Surgery Are Better Than Cemiplimab (REGN2810) Alone in Patients With Stage III-IV Head and Neck Cancer
Phase 2
Not yet recruiting
- Conditions
- Recurrent Head and Neck Cutaneous Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaRecurrent Hypopharyngeal Squamous Cell CarcinomaRecurrent Laryngeal Squamous Cell CarcinomaRecurrent Oral Cavity Squamous Cell CarcinomaRecurrent Oropharyngeal Squamous Cell CarcinomaStage III Head and Neck Cutaneous Squamous Cell Carcinoma AJCC v8Stage III Laryngeal Cancer AJCC v8Stage III Lip and Oral Cavity Cancer AJCC v8Stage III Nasopharyngeal Carcinoma AJCC v8
- Interventions
- Procedure: Biospecimen CollectionBiological: Anti-CD40 Agonist Monoclonal Antibody CDX-1140Procedure: Biopsy ProcedureProcedure: Computed TomographyProcedure: Positron Emission TomographyProcedure: Tumor Resection
- First Posted Date
- 2025-05-20
- Last Posted Date
- 2025-05-20
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 44
- Registration Number
- NCT06980038
Study for Patients With Hairy Cell Leukemia to Test the Targeted Agent Tovorafenib in Combination With Rituximab and Compare the Combination With Current Standard Treatment
Phase 1
Not yet recruiting
- Conditions
- Hairy Cell LeukemiaRecurrent Hairy Cell LeukemiaRefractory Hairy Cell Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Computed Tomography
- First Posted Date
- 2025-05-11
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 78
- Registration Number
- NCT06965114
Venetoclax or Placebo in Combination With Reduced-Intensity Conditioning Hematopoietic Cell (Bone Marrow/Blood Stem Cell) Transplant and as Maintenance Therapy After Transplant in Patients With Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)
Phase 2
Not yet recruiting
- Conditions
- Acute Myeloid Leukemia
- Interventions
- Procedure: Allogeneic Hematopoietic Stem Cell TransplantationProcedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Chest RadiographyProcedure: Computed TomographyProcedure: Echocardiography TestProcedure: Multigated Acquisition ScanDrug: Placebo AdministrationProcedure: Positron Emission TomographyRadiation: Total-Body Irradiation
- First Posted Date
- 2025-05-02
- Last Posted Date
- 2025-05-11
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 244
- Registration Number
- NCT06954987
Testing the Investigational Medication Combination of Daratumumab and Teclistamab Compared to the Usual Treatment (Daratumumab, Pomalidomide, Dexamethasone or Daratumumab, Carfilzomib, Dexamethasone) for Patients With High-risk Multiple Myeloma Refractory or in First Relapse
Phase 2
Not yet recruiting
- Conditions
- Recurrent Multiple MyelomaRefractory Multiple Myeloma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow BiopsyProcedure: Computed TomographyProcedure: FDG-Positron Emission Tomography
- First Posted Date
- 2025-04-29
- Last Posted Date
- 2025-05-07
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 80
- Registration Number
- NCT06948084
Testing the Addition of Venetoclax or Gemtuzumab Ozogamicin (GO) to Usual Treatment Regimen (Cytarabine and Daunorubicin, "7+3") for Core Binding Factor Acute Myeloid Leukemia (CBF-AML) to Improve Response (A MyeloMATCH Treatment Trial)
Phase 2
Not yet recruiting
- Conditions
- Core Binding Factor Acute Myeloid Leukemia
- Interventions
- Procedure: Biospecimen CollectionProcedure: Bone Marrow AspirationProcedure: Bone Marrow BiopsyProcedure: Echocardiography TestProcedure: Multigated Acquisition Scan
- First Posted Date
- 2025-04-09
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 162
- Registration Number
- NCT06917911
Autologous T Cells Transduced With Retroviral Vectors Expressing TCRs for Participant-specific Neoantigens in Patients With Hematologic Malignancies
Phase 1
Not yet recruiting
- Conditions
- Malignancy, HematologicNeoplasms, HematologicNeoplasms, HematopoieticBlood CancerHematological NeoplasmsHematopoietic MalignanciesDysmyelopoietic SyndromesHematopoetic MyelodysplasiaMyeloid Leukemia, AcuteNonlymphoblastic Leukemia, Acute
- Interventions
- Biological: Individual Patient TCR-Transduced PBLDevice: TruSight Oncology (TSO) 500
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-05-21
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 86
- Registration Number
- NCT06904066
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Testing the Addition of an Anti-Cancer Drug, Cabozantinib to the Immunotherapy Drug Cemiplimab (REGN2810), in Adolescents and Adults With Advanced Adrenocortical Cancer
Phase 2
Not yet recruiting
- Conditions
- Locally Advanced Adrenal Cortical CarcinomaMetastatic Adrenal Cortical CarcinomaRecurrent Adrenal Cortical CarcinomaStage III Adrenal Cortical Carcinoma AJCC v8Stage IV Adrenal Cortical Carcinoma AJCC v8Unresectable Adrenal Cortical Carcinoma
- Interventions
- Procedure: Biospecimen CollectionProcedure: Computed TomographyProcedure: Magnetic Resonance Imaging
- First Posted Date
- 2025-03-28
- Last Posted Date
- 2025-04-06
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 48
- Registration Number
- NCT06900595
Testing an Anti-cancer Radio-Active Immunotherapy Called Lintuzumab Ac225 in Patients With High-Risk Myelodysplastic Syndrome That Has Not Responded to Other Treatment
Phase 1
Not yet recruiting
- Conditions
- Refractory Myelodysplastic Syndrome
- First Posted Date
- 2025-03-21
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 30
- Registration Number
- NCT06888323
Anti-Mesothelin TNaive/SCM hYP218 (TNhYP218) CAR T Cells in Participants With Mesothelin-Expressing Solid Tumors Including Mesothelioma
Phase 1
Not yet recruiting
- Conditions
- MesotheliomaNeoplasmsStomach NeoplasmsPancreatic NeoplasmsOvarian NeoplasmsLung NeoplasmsThymus NeoplasmsColonic Neoplasms
- Interventions
- Device: mesothelin expression testingBiological: TNhYP217 CAR T Cells
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-03-24
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 100
- Registration Number
- NCT06885697
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
© Copyright 2025. All Rights Reserved by MedPath